TVTX Q3 2019 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+9.0% YoY

Gross Profit

$43M96.6% margin

Operating Income

-$34M-77.6% margin

Net Income

-$36M-82.2% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

-0.7%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$18M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$614M

Total Liabilities

$368M

Stockholders' Equity

$246M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$41M	+9.0%
Gross Profit	$43M	$40M	+8.3%
Operating Income	-$34M	-$36M	+3.2%
Net Income	-$36M	-$55M	+33.1%

Revenue Segments

Tiopronin Products

$24M55%

Bile Acid Products

$20M45%